Easton Pharmaceuticals Initiates Discussions With Canadian Medical Marijuana Association / Club
TORONTO, ON–(Marketwired – Dec 10, 2014) – Easton Pharmaceuticals (OTC: EAPH) announces it has started discussions with a Canadian Medical Marijuana Club.
Alongside its other business segments, Easton has been seeking acquisition targets in the areas of legal marijuana grow operations, patient access, patentable marijuana plant strains in the United States as well as Canada. As a result, Easton has initiated discussions with a Private Medical Marijuana Club, located in Toronto, Canada regarding a direct capital investment. This Club currently has a database of members as well as existing relationships with MMPR Licensed providers. The Marijuana club currently contains a database of members / patients with medical diagnosis and prescriptions who are able to match and provide patients with appropriate strains of Marijuana as well as match provider’s who might have those strains available for sale at the time. The club can be more efficient at contacting and informing any members if a batch is recalled providing a layer of safety to its members.
Easton Management believes that having access to patients will be the key to being successful in the Canadian Marketplace. Health Canada has taken a very draconian stance on MMPR’s and how they are allowed to market Marijuana as it’s scheduled as a narcotic in Canada.
Health Canada has issued warning letters to nearly every MMPR license holder towards their marketing practices.
“On November 25, 2014, Health Canada issued warning letters to 20 licensed producers regarding their advertising practices. These warning letters are in follow-up to an advertising bulletin sent to all licensed producers on June 30, 2014, that outlined the general prohibitions against the advertising of Cannabis contained in the Marihuana for Medical Purposes Regulations (MMPR), the Food and Drugs Act (FDA) and the Narcotic Control Regulations (NCR).
As a result of these prohibitions, the information provided by licensed producers to the public should be limited to basic information for prospective clients such as the brand name, proper or common name of the strain, the price per gram, the cannabinoid content, and the company’s contact information.
The licensed producers listed below have been given until January 12, 2015, to come into compliance with the advertising prohibitions following which, Health Canada will initiate appropriate enforcement action. Health Canada will update this list as licensed producers become compliant.
Licensed producers for which Health Canada has issued warning letters
The companies listed have been issued warning letters and have until January 12, 2015, to come into compliance.
- Bedrocan Canada Inc.
- Broken Coast Cannabis Ltd.
- CannMedica Pharma Inc.
- CanniMed Inc.
- Delta 9 Bio-Tech Inc.
- In the Zone Produce Ltd.
- MariCann Inc.
- MedReleaf Corp.
- Mettrum Ltd.
- OrganiGram Inc.
- Prairie Plant Systems Inc.
- The Peace Naturals Project Inc.
- ThunderBird Biomedical Inc.
- Tweed Inc.
- Whistler Medical Marijuana Corp.
Additional Information on Easton Pharmaceuticals Inc can be found at
About Easton Pharmaceuticals
Easton Pharmaceuticals is a specialty pharmaceutical company involved in various pharmaceutical sectors and others industries such as medical marijuana. The Company previously owned an FDA approved wound healing drug and currently owns topically-delivered drugs and therapeutic / cosmetic healthcare products focused on cancer and other health issues geared towards female sexual dysfunction, wound healing, pain, motion sickness and other conditions that are all in various stages of development. The company has ventured into the potentially lucrative medical marijuana industry through an investment into AMFIL Technologies and their groZONE anti-bacterial system and the exclusive option to purchase up to 49% in a medical marijuana grow-op business / facility which has received a letter to build from Health Canada. The company’s gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of Cannabidiol extracts.
For More Information Visit:
This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The “Act”). In particular, when certain words or phrases such as “hope”, “positive”, “anticipate,” “pleased,” “plan,” “confident that,” “believe,” “expect,” “possible” or “intent to” and similar conditional expressions are expressed, they are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals would be classified as speculative and may contain risks. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company’s products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company’s financial reports and filings.
Tel: +1(416) 619-0291
Tel: +1(347) 284-0192
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | email@example.com